Interpharm Holdings (IPAH) Fair Value & Analysis
Healthcare · US · Market cap $5.0K
Interpharm Holdings
IPAH · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $79.69 to $0.0032 (−100.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0032 – $0.0032 · fair‑value band $0.0031 – $0.0032 · the $0.0032 price screens above the $0.0032 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Interpharm Holdings (IPAH) currently trades at $0.0032, while our model-based Fair Value estimate is $0.0032 — implying the stock looks roughly 0.4% overvalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Interpharm Holdings generated revenue of $69.2M at a net margin of -42.4%. Revenue declined 7.2% year over year. Fundamentals as of Jun 26, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Interpharm Holdings, Inc. develops, manufactures, and markets generic prescription strength and over-the-counter pharmaceuticals. The company supplies its medicines to major retailers, wholesalers, managed care organizations, and national distributors. The company was founded in 1984 and is based in Hauppauge, New York.
Revenue & earnings trend
FY2003 – FY2007 · reported fiscal years
Interpharm Holdings reported revenue of $75.6M in FY2007 versus $27.5M in FY2003, a compound +28.7%/yr. Reported net income was −$14.1M in FY2007.
Is IPAH fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,863 | ₹1,039 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Interpharm Holdings (IPAH) undervalued?
What is the fair value of IPAH?
What is the quality score of IPAH?
What is the revenue of Interpharm Holdings (IPAH)?
What is the net profit margin of IPAH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.